Consolidated EBITDA dropped 26 percent YoY to Rs 16.27 crore while operating margin contracted sharply to 13.07 percent from 22.32 percent a year ago.

Tatva Chintan Pharma drops 8% as margin disappoints

Tatva Chintan Pharma’s net profit declined 49.06 per cent to Rs 11.62 crore in Q3 FY23 as against Rs 22.81 crore during the same period a year ago.

Tatva Chintan Pharma Chem shares tank 5% after Q3 results; what’s next: Rs 1,950 or Rs 2,200?

TVS Motor has plans to launch a series of EV models in the range of 5-25kwh, both in two- and three-wheeler segments over the next two years

Stocks to buy: Tatva Chintan, SKF India, TVS Motor & Mas Financial

One year lock-in of Tatva Chintan Pharma, Rolex Rings, Glenmark Life Sciences shares are soon going to end

Rolex Rings to CarTrade: One year lock-in of these 5 stocks to end soon

Tatva Chintan Q1 Review - Near Term Pressure In SDAs; Working On Multiple Opportunities: Nirmal Bang

Here’s what brokerages have to say about Tatva Chintan’s Q1 FY23 results.

Tatva Chintan Tumbles As Analysts Flag Key Near-Term Concerns After Q1

Tatva Chintan Pharma Chemicals made a strong debut on bourses today, with its share listing 95% higher to the issue price.

Tatva Chintan Pharma shares tank over 10% as Q4 profit declines 17%

ICICI Securities is bullish on Tatva Chintan Pharma Chem has recommended buy rating on the stock with a target price of Rs 2875 in its research report dated April 26, 2022.

Buy Tatva Chintan Pharma Chem: target of Rs 2875: ICICI Securities

At 10:28 IST, the barometer index, S&P BSE Sensex rallied 643.1 points or 1.14% at 57,223.13. The Nifty 50 index added 203.65 points or 1.2% at 17,157.

Nifty above 17,150; Tatva Chintan down 7%

Tatva Chintan Pharma Chem fell 7.82% to Rs 2303 after the company’s consolidated net profit declined 17.09% to Rs 17.51 crore on 9.33% decline in net sales to Rs 98.53 crore in Q4 March 2022 over Q4 March 2021.

Tatva Chintan Pharma drops after Q4 PAT slides 17% YoY

Tatva Chintan Standalone March 2022 Net Sales at Rs 101.88 crore, down 2.5% Y-o-Y

Hasn't faired well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Tatva Chintan Pharma Chem is engaged in the manufacturing business  of chemical products.